Patent · US Active

Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis

US11919959B2 · kind B2 · utility

0Cited by
20References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 13, 2020
Grant dateMar 5, 2024
Priority date
Expiry dateOct 4, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.